# Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Source: https://onco.cc/trials/nct04415853/  
OnCo record `nct04415853` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Lerotinib in oesophageal cancer, now recruiting.

## Summary

Study of Larotinib in Unresectable Advanced or Recurrent Oesophageal Cancer is a phase 3 interventional study registered as NCT04415853, led by Sunshine Lake Pharma, and recruiting on the registry. Official title: Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Oesophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study. Planned enrolment is 416 participants (estimated). The study started in 2021-01-21 and primary completion is expected in 2026-08. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT04415853
- Phase: 3
- Setting: Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study
- Sponsor: Sunshine Lake Pharma
- Enrolled: 416

## Sources

- ClinicalTrials.gov NCT04415853: https://clinicaltrials.gov/study/NCT04415853

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Oesophageal squamous cell carcinoma](https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/)
- drugs: [Lerotinib](https://onco.cc/drugs/lerotinib/)
- companies: [Sunshine Lake Pharma (HEC)](https://onco.cc/companies/sunshine-lake-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04415853.json